KR20230118751A - System for providing metaverse platform connecting between pharmaceutical company, contract sales organization, doctor and patient - Google Patents

Abstract

A metaverse platform service providing system that connects pharmaceutical companies, CSOs, doctors and patients is provided, and pharmaceutical company terminals that upload pharmaceutical company data including products, academic and marketing materials, and CSO (Contract Sales Organization) that receives pharmaceutical company data from pharmaceutical company terminals Doctor terminal that selects and calls the CSO of the terminal and CSO terminal and receives pharmaceutical company data from the CSO terminal, selects a doctor from the doctor terminal and receives non-face-to-face telemedicine, patient terminal and pharmaceutical company terminal, CSO terminal, doctor terminal and patient terminal A construction unit that builds the connected metaverse platform, a CSO management unit that receives CSO registration from CSO terminals and builds a human resource pool, an upload unit that receives pharmaceutical company data from pharmaceutical company terminals, and information from CSO terminals to doctor terminals using pharmaceutical company data. and receive pharmaceutical company data by selectively calling the CSO terminal from the doctor terminal, direct performance reporting unit that delivers business results to the pharmaceutical company terminal when a prescription is issued, and non-face-to-face when a patient terminal designates a doctor at the doctor terminal and a platform service providing server including a remote medical treatment unit for conducting remote medical treatment.

Description

Metaverse platform service providing system that connects pharmaceutical companies, CSOs, doctors and patients

The present invention relates to a metaverse platform service providing system that connects pharmaceutical companies, CSOs, doctors and patients, directly connecting pharmaceutical companies and CSOs within the metaverse platform, and incorporating doctors and patients into non-face-to-face telemedicine to the platform. It provides a system for participation.

South Korea's economic order is based on a capitalist market economy based on respect for economic freedom and creativity of individuals and companies. In order for the market to function normally, free and fair competition is necessary. Here, fair competition is quality and cheap competition through the quality and price of products or services. Competition in Korea's pharmaceutical and health care markets is also vigorous, and when the competition is based on price and quality, patients or insurers in the position of buyers or consumers benefit from the competition. However, pharmaceutical rebates hinder price and quality competition in the pharmaceutical and health care markets, that is, fair competition, and hinder efficient resource allocation by preventing the normal functioning of the pharmaceutical and health care markets. Because rebate competition is possible without any special skills or knowledge and is conducted negatively, in this market environment, the number of small pharmaceutical companies without differentiated competitiveness in terms of price or quality increases. Domestic pharmaceutical companies that have consumed their resources in rebate competition will not be able to demonstrate their full capacity in overseas markets where they have to compete on price or quality competitiveness.

At this time, a platform that supports purchase through matching drug salespersons, pharmaceutical companies, and hospitals or analyzing purchase patterns of hospitals and pharmacies has been researched and developed. Announced on July 8) and Korean Registered Patent No. 10-1860702 (Announced on May 23, 2018), pharmaceutical companies and sales agencies share a collaboration process on the platform, pharmaceutical companies promote products within the platform, In addition, pharmaceutical companies provide real-time drug information, provide price comparison of drugs delivered to hospitals and pharmacies, and manage drug inventory through drug inventory management. In order to reduce the inconvenience of ordering, configurations for analyzing purchase patterns of hospitals and pharmacies are disclosed.

However, the former configuration is only a configuration that mediates pharmaceutical companies, sales agents, and salespersons on the platform, and the latter configuration discloses only the known technology of analyzing purchase patterns for drug inventory management. Since the rebate double penalty system in 2010 and the Korean version of the K-Sunshine Act in 2018 were initiated, rebate activities by pharmaceutical companies have been restricted due to the strengthening of the Fair Trade Compliance Program, but rebate activities by CSOs (Contract Sales Organizations) There has been constant criticism that the drug is circumventing the law, and the government is stepping up regulation by incorporating CSO, a sales agency, as a person entrusted with sales promotion work from drug suppliers in accordance with Articles 47 and 47-2 of the Pharmaceutical Affairs Act in 2021. Accordingly, research and development of a platform that connects doctors, pharmaceutical companies, CSOs, and patients to one metaverse platform, enabling pharmaceutical companies to form reasonable prices through free competition, and allowing CSOs to report sales performance directly to pharmaceutical companies. this is required

One embodiment of the present invention connects doctors, pharmaceutical companies, CSOs, and patients to the Metaverse platform, allows pharmaceutical companies to form reasonable prices through free competition without rebates, and direct contact with pharmaceutical companies by the corporate CSO. Anyone who has been difficult to participate as a CSO can directly sign contracts with pharmaceutical companies and report sales performance directly, doctors receive marketing and information from the CSO, doctors search for product information from pharmaceutical companies, and pharmaceutical companies as CSOs It is possible to provide a metabus platform service delivery system that connects pharmaceutical companies, CSOs, doctors and patients, providing academic data and marketing, and allowing doctors to treat patients non-face-to-face. However, the technical problem to be achieved by the present embodiment is not limited to the technical problem as described above, and other technical problems may exist.

As a technical means for achieving the above technical problem, an embodiment of the present invention is a pharmaceutical company terminal that uploads pharmaceutical company data including products, academic and marketing data, and a CSO (Contract Sales Organization) that receives pharmaceutical company data from the pharmaceutical company terminal. Doctor terminal that selects and calls the CSO of the terminal and CSO terminal and receives pharmaceutical company data from the CSO terminal, selects a doctor from the doctor terminal and receives non-face-to-face telemedicine, patient terminal and pharmaceutical company terminal, CSO terminal, doctor terminal and patient terminal A construction unit that builds the connected metaverse platform, a CSO management unit that receives CSO registration from CSO terminals and builds a human resource pool, an upload unit that receives pharmaceutical company data from pharmaceutical company terminals, and information from CSO terminals to doctor terminals using pharmaceutical company data. and receive pharmaceutical company data by selectively calling the CSO terminal from the doctor terminal, direct performance reporting unit that delivers business results to the pharmaceutical company terminal when a prescription is issued, and non-face-to-face when a patient terminal designates a doctor at the doctor terminal and a platform service providing server including a remote medical treatment unit for conducting remote medical treatment.

According to any one of the above-described problem solving means of the present invention, doctors, pharmaceutical companies, CSOs, and patients are connected to the metaverse platform, pharmaceutical companies form reasonable prices through free competition without rebates, and CSOs are formed by corporate CSOs. It is difficult to directly contact pharmaceutical companies, so that any individual can participate as a CSO to directly sign contracts with pharmaceutical companies and report sales performance directly. Doctors receive marketing and information from CSOs, doctors search product information from pharmaceutical companies, , Pharmaceutical companies deliver products to CSOs, provide academic materials and marketing, and allow doctors to treat patients non-face-to-face.

1 is a diagram for explaining a metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients according to an embodiment of the present invention.
FIG. 2 is a block diagram illustrating a platform service providing server included in the system of FIG. 1 .
3 and 4 are diagrams for explaining an embodiment in which a metaverse platform service that connects pharmaceutical companies, CSOs, doctors, and patients according to an embodiment of the present invention is implemented.
5 is an operation flow chart for explaining a method of providing metaverse platform services that connect pharmaceutical companies, CSOs, doctors, and patients according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily practice the present invention with reference to the accompanying drawings. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein. And in order to clearly explain the present invention in the drawings, parts irrelevant to the description are omitted, and similar reference numerals are attached to similar parts throughout the specification.

Throughout the specification, when a part is said to be "connected" to another part, this includes not only the case where it is "directly connected" but also the case where it is "electrically connected" with another element interposed therebetween. . In addition, when a part "includes" a certain component, this means that it may further include other components, not excluding other components, unless otherwise stated, and one or more other characteristics. However, it should be understood that it does not preclude the possibility of existence or addition of numbers, steps, operations, components, parts, or combinations thereof.

As used throughout the specification, the terms "about", "substantially", etc., are used at or approximating that value when manufacturing and material tolerances inherent in the stated meaning are given, and do not convey an understanding of the present invention. Accurate or absolute figures are used to help prevent exploitation by unscrupulous infringers of the disclosed disclosure. The term "step of (doing)" or "step of" as used throughout the specification of the present invention does not mean "step for".

In this specification, a "unit" includes a unit realized by hardware, a unit realized by software, and a unit realized using both. Further, one unit may be realized using two or more hardware, and two or more units may be realized by one hardware. On the other hand, '~ unit' is not limited to software or hardware, and '~ unit' may be configured to be in an addressable storage medium or configured to reproduce one or more processors. Thus, as an example, '~unit' refers to components such as software components, object-oriented software components, class components, and task components, processes, functions, properties, and procedures. , subroutines, segments of program code, drivers, firmware, microcode, circuitry, data, databases, data structures, tables, arrays and variables. Functions provided within components and '~units' may be combined into smaller numbers of components and '~units' or further separated into additional components and '~units'. In addition, components and '~units' may be implemented to play one or more CPUs in a device or a secure multimedia card.

In this specification, some of the operations or functions described as being performed by a terminal, device, or device may be performed instead by a server connected to the terminal, device, or device. Likewise, some of the operations or functions described as being performed by the server may also be performed by a terminal, apparatus, or device connected to the server.

In this specification, some of the operations or functions described as mapping or matching with the terminal mean mapping or matching the terminal's unique number or personal identification information, which is the terminal's identifying data. can be interpreted as

Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.

1 is a diagram for explaining a metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients according to an embodiment of the present invention. Referring to FIG. 1, the metaverse platform service providing system 1 connecting pharmaceutical companies, CSOs, doctors and patients includes at least one patient terminal 100, a platform service providing server 300, and at least one pharmaceutical company terminal ( 400), at least one CSO terminal 500 and pseudo terminal 600. However, since the metaverse platform service providing system 1 connecting pharmaceutical companies, CSOs, doctors and patients in FIG. 1 is only one embodiment of the present invention, the present invention is not limited to interpretation through FIG. 1.

At this time, each component of FIG. 1 is generally connected through a network (Network, 200). For example, as shown in FIG. 1 , at least one patient terminal 100 may be connected to a platform service providing server 300 through a network 200 . In addition, the platform service providing server 300 connects at least one patient terminal 100, at least one pharmaceutical company terminal 400, at least one CSO terminal 500, and a doctor terminal 600 through the network 200. can be connected In addition, at least one pharmaceutical company terminal 400 may be connected to the platform service providing server 300 through the network 200 . In addition, at least one CSO terminal 500 may be connected to at least one patient terminal 100, the platform service providing server 300, and at least one pharmaceutical company terminal 400 through the network 200. Finally, the doctor terminal 600 may be connected to the patient terminal 100, the pharmaceutical company terminal 400, the platform service providing server 300, and at least one CSO terminal 500 through the network 200.

Here, the network refers to a connection structure capable of exchanging information between nodes such as a plurality of terminals and servers, and examples of such networks include a local area network (LAN) and a wide area network (WAN: Wide Area Network), the Internet (WWW: World Wide Web), wired and wireless data communications networks, telephone networks, and wired and wireless television communications networks. Examples of wireless data communication networks include 3G, 4G, 5G, 3rd Generation Partnership Project (3GPP), 5th Generation Partnership Project (5GPP), Long Term Evolution (LTE), World Interoperability for Microwave Access (WIMAX), Wi-Fi , Internet (Internet), LAN (Local Area Network), Wireless LAN (Wireless Local Area Network), WAN (Wide Area Network), PAN (Personal Area Network), RF (Radio Frequency), Bluetooth (Bluetooth) network, NFC ( A Near-Field Communication (Near-Field Communication) network, a satellite broadcasting network, an analog broadcasting network, a Digital Multimedia Broadcasting (DMB) network, etc. are included, but not limited thereto.

In the following, the term at least one is defined as a term including singular and plural, and even if at least one term does not exist, each component may exist in singular or plural, and may mean singular or plural. It will be self-evident. In addition, the singular or plural number of each component may be changed according to embodiments.

At least one patient terminal 100 may be a terminal of a patient who receives non-face-to-face telemedicine using a web page, app page, program, or application related to the metaverse platform service that connects pharmaceutical companies, CSOs, doctors, and patients.

Here, at least one patient terminal 100 may be implemented as a computer capable of accessing a remote server or terminal through a network. Here, the computer may include, for example, a laptop, a desktop, a laptop, and the like equipped with a navigation system and a web browser. In this case, at least one patient terminal 100 may be implemented as a terminal capable of accessing a remote server or terminal through a network. At least one patient terminal 100 is, for example, a wireless communication device that ensures portability and mobility, and includes navigation, personal communication system (PCS), global system for mobile communications (GSM), personal digital cellular (PDC), PHS (Personal Handyphone System), PDA (Personal Digital Assistant), IMT (International Mobile Telecommunication)-2000, CDMA (Code Division Multiple Access)-2000, W-CDMA (W-Code Division Multiple Access), Wibro (Wireless Broadband Internet ) may include all types of handheld-based wireless communication devices such as terminals, smartphones, smart pads, tablet PCs, and the like.

The platform service providing server 300 may be a server that provides a metaverse platform service web page, app page, program or application connecting pharmaceutical companies, CSOs, doctors and patients. In addition, the platform service providing server 300 is a server that registers the patient terminal 100, the pharmaceutical company terminal 400, the CSO terminal 500, and the doctor terminal 600 and connects them to communicate with each other on the metaverse platform. can In addition, the platform service providing server 300 may be a server that allows the CSO terminal 500 to directly report business results to the pharmaceutical company terminal 400 . The platform service providing server 300 may be a server that allows the pharmaceutical company terminal 400 to form a reasonable drug price according to free market competition.

Here, the platform service providing server 300 may be implemented as a computer capable of accessing a remote server or terminal through a network. Here, the computer may include, for example, a laptop, a desktop, a laptop, and the like equipped with a navigation system and a web browser.

At least one pharmaceutical company terminal 400 may be a pharmaceutical company terminal using a metaverse platform service-related web page, app page, program, or application that connects pharmaceutical companies, CSOs, doctors, and patients. In addition, at least one pharmaceutical company terminal 400 uploads pharmaceutical company data including products, academic materials, marketing, etc. necessary for pharmaceutical sales directly to the CSO terminal 500 or to the platform service providing server 300, and then to the pharmaceutical company terminal ( 400) may be a terminal that allows access by the CSO terminal 500 that has entered into a contract. In addition, the pharmaceutical company terminal 400 may be a terminal requesting a sales performance report directly from the CSO terminal 500, and may be a server that directly settles costs for this to the CSO terminal 500.

Here, at least one pharmaceutical company terminal 400 may be implemented as a computer capable of accessing a remote server or terminal through a network. Here, the computer may include, for example, a laptop, a desktop, a laptop, and the like equipped with a navigation system and a web browser. In this case, at least one pharmaceutical company terminal 400 may be implemented as a terminal capable of accessing a remote server or terminal through a network. At least one pharmaceutical company terminal 400 is, for example, a wireless communication device that ensures portability and mobility, and includes navigation, PCS (Personal Communication System), GSM (Global System for Mobile communications), PDC (Personal Digital Cellular), PHS (Personal Handyphone System), PDA (Personal Digital Assistant), IMT (International Mobile Telecommunication)-2000, CDMA (Code Division Multiple Access)-2000, W-CDMA (W-Code Division Multiple Access), Wibro (Wireless Broadband Internet ) may include all types of handheld-based wireless communication devices such as terminals, smartphones, smart pads, tablet PCs, and the like.

At least one CSO terminal 500 may be a terminal of an individual or company that conducts pharmaceutical business using a metaverse platform service-related web page, app page, program, or application that connects pharmaceutical companies, CSOs, doctors, and patients. The CSO terminal 500 may be a terminal that receives marketing data, academic data, product data, etc. for pharmaceutical sales after making a direct contract with the pharmaceutical company terminal 400 . In addition, the CSO terminal 500 may be a terminal that visits the doctor's hospital within the metaverse platform to conduct marketing and information delivery when receiving a selection call from the doctor terminal 600, and directly reports sales results when a prescription is issued. It may be a terminal reporting to the pharmaceutical company terminal 400 .

Here, at least one CSO terminal 500 may be implemented as a computer capable of accessing a remote server or terminal through a network. Here, the computer may include, for example, a laptop, a desktop, a laptop, and the like equipped with a navigation system and a web browser. In this case, at least one CSO terminal 500 may be implemented as a terminal capable of accessing a remote server or terminal through a network. At least one CSO terminal 500 is, for example, a wireless communication device that ensures portability and mobility, and includes navigation, PCS (Personal Communication System), GSM (Global System for Mobile communications), PDC (Personal Digital Cellular), PHS (Personal Handyphone System), PDA (Personal Digital Assistant), IMT (International Mobile Telecommunication)-2000, CDMA (Code Division Multiple Access)-2000, W-CDMA (W-Code Division Multiple Access), Wibro (Wireless Broadband Internet ) may include all types of handheld-based wireless communication devices such as terminals, smartphones, smart pads, tablet PCs, and the like.

The doctor terminal 600 is connected to the patient terminal 100 within the metaverse platform using a web page, app page, program or application related to the metaverse platform service that connects pharmaceutical companies, CSOs, doctors and patients, and provides non-face-to-face treatment. It may be a doctor's terminal that performs and selectively calls the CSO of the CSO terminal 500 to receive marketing data or academic data.

Here, the pseudo terminal 600 may be implemented as a computer capable of accessing a remote server or terminal through a network. Here, the computer may include, for example, a laptop, a desktop, a laptop, and the like equipped with a navigation system and a web browser. In this case, the pseudo terminal 600 may be implemented as a terminal capable of accessing a remote server or terminal through a network. The pseudo terminal 600 is, for example, a wireless communication device that ensures portability and mobility, and includes navigation, PCS (Personal Communication System), GSM (Global System for Mobile communications), PDC (Personal Digital Cellular), PHS (Personal Communication System) Handyphone System), PDA (Personal Digital Assistant), IMT (International Mobile Telecommunication)-2000, CDMA (Code Division Multiple Access)-2000, W-CDMA (W-Code Division Multiple Access), Wibro (Wireless Broadband Internet) terminal, It may include all kinds of handheld-based wireless communication devices such as a smartphone, a smart pad, a tablet PC, and the like.

2 is a block diagram illustrating a platform service providing server included in the system of FIG. 1, and FIGS. 3 and 4 are metaverse platforms that connect pharmaceutical companies, CSOs, doctors and patients according to an embodiment of the present invention. It is a diagram for explaining an embodiment in which the service is implemented.

Referring to FIG. 2, the platform service providing server 300 includes a construction unit 310, a CSO management unit 320, an upload unit 330, a direct performance report unit 340, a remote medical treatment unit 350, and a medical data system. It may include study 360, payment unit 370, statistics unit 380, reproduction unit 390, rebate report unit 391, penalty provision unit 393 and shopping mall provision unit 395.

The platform service providing server 300 according to an embodiment of the present invention or another server (not shown) operating in conjunction with at least one patient terminal 100, at least one pharmaceutical company terminal 400, and at least one CSO terminal 500 and at least one doctor terminal 600, in the case of transmitting a metaverse platform service application, program, app page, web page, etc. that connects pharmaceutical companies, CSOs, doctors and patients, at least one patient terminal 100 , At least one pharmaceutical company terminal 400, at least one CSO terminal 500, and at least one doctor terminal 600 are metaverse platform service applications, programs, app pages that connect pharmaceutical companies, CSOs, doctors and patients, You can install or open web pages, etc. In addition, a service program is implemented in at least one patient terminal 100, at least one pharmaceutical company terminal 400, at least one CSO terminal 500, and at least one doctor terminal 600 by using a script executed in a web browser. may be driven. Here, the web browser is a program that allows users to use the web (WWW: World Wide Web) service, and means a program that receives and displays hypertext described in HTML (Hyper Text Mark-up Language). For example, Netscape , Explorer, Chrome, and the like. In addition, an application means an application on a terminal, and includes, for example, an app running on a mobile terminal (smart phone).

Before describing FIG. 2 , the basic concept of drug rebates and CSOs will be described below. Details described below will not be repeated while referring to FIG. 2 .

<Pharmaceutical rebates>

The dictionary meaning of rebate is refund or discount. In general, rebate is understood as a discount method in which a seller provides economic benefits by refunding a portion of sales to a buyer to promote sales. Such rebates may be exceptionally violating the Fair Trade Act as conditional rebates, etc., but they are generally a desirable phenomenon for buyers or consumers because they are the result of price competition. However, if the person receiving the kickback is not a buyer or consumer, but a person who has influence over the purchase decision, the kickback has the same character as a kickback. A representative example is drug rebates.

<Reasons for regulating drug rebates>

<Protection of public health and reduction of medical expenses>

In Korea, drug rebates are pointed out as a chronic disease in the health care sector. For example, if you search for drug rebates on an Internet search site and look at related articles, there are only articles that report negatively on drug rebates, but no articles that evaluate them positively. The reason pharmaceutical rebates are evaluated negatively is that they can threaten public health and unreasonably increase medical expenses. The Supreme Court held that drug rebates lead to the sale of unnecessary drugs to consumers, which is highly likely to cause misuse and abuse of drugs, and there is a risk of adversely affecting public health. It is the position that it not only leads to an increase, but eventually causes the deterioration of the health insurance finance, and the burden is actually passed on to the people who have only limited options for medicines (Supreme Law 2012du 7608). The Anti-Corruption and Civil Rights Commission believes that drug rebates distort the transparent distribution order of drugs, increase the public's burden of medical expenses, and worsen the health insurance finances.

<Promoting desirable competition in the pharmaceutical and health care markets>

Pharmaceutical rebates also hinder fair competition in the healthcare market. Among medical providers such as doctors, if those who effectively receive drug rebates can generate more business profits and have a competitive advantage, fair competition will be hindered. If such a structure deepens, providers who do not receive drug rebates may be left behind in competition. There may be cases where hospitals or clinics use pharmaceutical rebate funds to expand facilities or hire personnel. If they expand their scale in this way and provide better medical services to gain an edge over other hospitals or clinics in the market, it is fair competition. cannot be regarded as a result of As such, drug rebate regulation is necessary to promote fair competition that benefits buyers or consumers according to price and quality in the Korean pharmaceutical and health care markets.

<CSO>

Pharmaceutical companies build sales organizations by hiring salespeople directly, building organizations through M&A, co-promotion and co-marketing, and outsourcing sales to CSOs. Among them, CSO (Contract Sales Organization) refers to a sales agent in charge of sales and marketing on behalf of a pharmaceutical company. CSOs provide services such as professional advertising and general consumer advertising, public relations, and medical education, as well as traditional salesperson dispatch services. In particular, sales outsourcing using CSOs has emerged as a strategic partner since the late 1990s, and the global CSO market size continues to increase. This is because sales outsourcing using a CSO has advantages over sales through the establishment of an internal sales organization, such as reduced initial investment, cost reduction, reduced time, improved expertise, and operational flexibility.

With CSO, the initial investment cost is low and fixed costs can be converted into variable costs, so assets can be invested in core businesses such as R&D and production. It is possible to build the necessary sales organization in a shorter time compared to training and putting it into the field. However, when used properly, CSOs, which have many advantages, are becoming a new window for illegal rebates in Korea, and corporate CSOs act as mediators for many individual CSOs, Medical Representatives and Medical Marketing Specialists. Because direct contact with pharmaceutical companies is limited, corporate CSOs take most of the fees, and MRs and MSs, who are platform workers, are not getting a fair price for their labor.

Accordingly, one embodiment of the present invention is to be able to meet all pharmaceutical companies, CSOs, doctors and patients within the metaverse platform, and to increase the influx of doctors by introducing doctors, customers of pharmaceutical companies, and patients, customers of doctors. In addition, doctors can provide telemedicine services to patients non-face-to-face, and CSOs can present and explain new drugs, product functions, academic data, etc. within the metaverse platform without having to meet and entertain doctors offline. In addition, pharmaceutical companies can improve the quality of medicines by investing the cost of rebates in R&D, and the National Health Insurance Corporation and the public can operate funds more actively and save pharmaceutical costs because the prices of medicines are reasonably adjusted. It is decided to provide a platform that can bring

Referring to FIG. 2 , the construction unit 310 may build a metaverse platform to which the pharmaceutical company terminal 400, the CSO terminal 500, the doctor terminal 600, and the patient terminal 100 are connected.

<Metaverse Framework>

The framework, which is a building block that composes the metaverse, is explained. The framework consists of 8 core stacks. ① Hardware corresponds to a physical device used in conjunction with the metaverse, and may include user devices such as AR and VR devices and an enterprise AR environment. . ② Networking can mean support for a metaverse distributed communication environment that provides real-time transmission of large amounts of data and seamless connectivity. It can include 5G and short-distance communication. ③ Compute may mean computing ability to support various and vast calculation functions such as physical calculation, real-time screen processing, and synchronization.

④ Virtual Platform can mean a virtualization platform that allows users to create an immersive experience by directly building or socializing a digital environment, unlike the way users consume developer's content on traditional online platforms. . ⑤ Interchange Tools and Standards can mean standards for technologies and protocols that support interoperability with the metaverse. ⑥ Payments can mean technical support for processes, platforms, and operations related to digital billing. It may correspond to Decentralized Finance (DeFi), NFT, and blockchain technology. ⑦ Metaverse Content, Services and Assets can mean the overall protection and management of metaverse digital assets, such as creation, processing, storage and service. ⑧ User Behaviors can refer to observable changes in the consumer and business aspects related to the metaverse. These behavioral changes generally mean trend changes and can include changes in interest in the metaverse or technological changes. For example, changes in the price of digital assets or changes in trading methods are applicable.

<Open Metaverse>

The open metaverse framework (Open Metaverse OS) is defined as a framework capable of selective combination of components based on Web 3.0. Considering that it operates on multiple virtual platforms or environments that support various virtual worlds such as the metaverse, an open framework that can be used in combination with components is more advantageous in terms of scalability than a fixed form that cannot be structurally changed. When modeling a virtual world from a platform perspective, it can have components similar to the metaverse framework stack structure. However, the emphasis on connecting the real world and the virtual world through a bridge is a differentiating factor. It can be interpreted that as the distance between the physical world (real world) and the virtual world (digital world) decreases, the evolution to the metaverse accelerates.

Among the major components of each component, ① User Persona corresponds to user information such as ID, name, and avatar, ② End User Hardware and Software corresponds to devices such as VR/AR headsets and related software, and ③ In -World Assets are assets that exist in the virtual world, ④ Physical (Virtual), means the space constituting the world and the buildings or objects that fill that space, ⑤ World Primitives and Rules, which describe the characteristics of the virtual world. ⑥ Bridges are the role of connecting the physical world and the digital world, that is, a method of connecting external systems and external environments.

The CSO management unit 320 may build a manpower pool by receiving CSO registration from the CSO terminal 500 . The CSO of the CSO terminal 500 may include a medical representative and a medical marketing specialist, and may include all of companies, corporations, and individuals as described above. Recently, according to the pharmaceutical industry, CSO companies are fiercely competing to recruit incumbent salespeople for pharmaceutical companies. Recruitment advertisements that entice people to sell products from other pharmaceutical companies with expensive commissions, namely sales incentives, are pouring in. These social conditions can be easily found on Internet bulletin boards, where salespeople of pharmaceutical companies are mainly active. CSO companies are recruiting salespeople with phrases such as on-site MR with excellent sales capabilities, direct contracts with pharmaceutical companies operating CSOs, strict confidentiality guarantees, strict tax guidelines, 100% performance structure, and relief from organizational stress. Both MR and MS, CSOs, are known to be top-notch sales professionals who have experienced all of the prenatal and prenatal skills in the pharmaceutical market, and are using their sales skills and personal networks to improve sales performance. However, if the CSO is a corporation rather than an individual, the operating cost that the pharmaceutical company must spend increases because the corporation acts as an intermediary, such as [pharmaceutical company-corporate CSO-individual CSO]. Accordingly, in one embodiment of the present invention, in order to establish a form in which individual CSOs are directly employed by pharmaceutical companies, a manpower pool may be established.

At this time, when constructing a human resource pool, the human network of each CSO can be identified using SNA (Social Network Analysis, hereinafter SNA). SNA is a methodology that analyzes data in the form of a network consisting of a series of entities and a set of relationships. SNA defines analysis indicators for structural analysis such as central structure, cohesive structure, and neighboring structure of the network. Recently, as data for analysis and calculation speed have improved, it is being used in various fields as an approach to understand various social phenomena, and social phenomena are networks composed of points (nodes, entities) and lines (links, relationships). It is a methodology to define and analyze.

One of the important things in network analysis like SNA is finding subgroups in a graph. A subgroup is composed of a subset within a network with homogenous interests or characteristics, and the interests among members or various group characteristics can be identified through analysis of the subgroup. This is also applied to algorithms that extract groups by finding similar nodes (nodes, points, objects, and hereinafter referred to as nodes) in a graph, or recommend content that has a similar connection to a node. In order to extract group groups in this way, a connection relationship must be defined, and for this, the similarity between all nodes must be calculated. In the process of calculating the similarity of the network, the similarity index used varies depending on whether or not the links constituting the network have weights. In general, Jaccard coefficients are often used when links do not have weights, and cosine similarity is often used when links have weights.

The Jacquard coefficient is a statistic for comparing the similarity of data included in two sets. The basic calculation method is to divide the size of data that the two sets have in common by the size of all the data that the two sets have, and is expressed by Equation 1 below. For example, there are generally more pharmaceutical companies that do not have contracts with a particular CSO than those that do. Therefore, it is possible to measure the similarity between CSO-affiliated pharmaceutical companies, excluding pharmaceutical companies to which both CSOs do not subscribe.

At this time, M11 is the number of data commonly possessed, M10 is the number of data that A (pharmaceutical company A) has alone, and M01 is the number of data that B (pharmaceutical company B) has alone.

Cosine similarity is often used to measure similarity in multidimensional positive space. In particular, since the network has such a multi-dimensional structure (link structure), it is a very useful method for measuring the similarity of two nodes in a network in which link weights are assigned. If the similarity is ‘1’, it is very similar, and if the similarity is ‘0’, it is not similar.

In this case, Ai or Bi denotes a weight that A or B has on the i-th link.

<Cycle Detection>

In SNA, the cycle detection algorithm is a structural analysis method that extracts a cycle with a direction within a network constructed through a specific relationship. In general, it is frequently used for fraud detection in various fields, and the algorithms used to detect cycles are very diverse, but the most commonly used algorithms are DFS (Depth-First Search)-based algorithms or Since cycle detection according to an embodiment of the present invention uses limiting conditions of cycle size and link type, it is a much more efficient method to use a DFS-based algorithm. Cycle detection algorithms generally perform analysis on directional networks, so they do not simply detect cycles based on connectivity alone. Therefore, for cycle detection ignoring directionality, analysis can be performed by bidirectionalizing (Symmetrizing) all links.

<Clique>

A network is composed of nodes (points, objects) and links (lines, relationships), and as one of the methods of examining the characteristics of a network, when nodes are connected to each other by links to form an agglomerated group, the nodes in the agglomerated group have a common Clique is one of the methods to quantify and calculate the cohesiveness of such a network. A cohesive structure means a structure in which connection relationships between nodes are dense, and a cohesive structure in SNA generally means a group or a set of function modules that perform the same function. In particular, clique is a method that has the most stringent constraints among the methods of extracting such a cohesive structure, and clique is established only when all nodes are directly connected to each other. Therefore, the link density inside the clique is 1. However, since clique depends only on the connection structure, it is not affected by the weight of the link. This makes it possible to classify structural suspect groups in the linkage analysis.

<Weak Component>

As one of the methods for defining a cohesive group, it is a graph of the maximum size in which all nodes are connected to each other through one or more paths. A weak component refers to a group in which all nodes are connected as one regardless of the direction of the link. For example, if there is a link from node A to node B, A and B are in one component. Nodes that exist in one component in this way mean that they are directly or indirectly related. In particular, in a link relationship with strict conditions, it means that there is considerable relevance in a set of nodes having the same weak component.

<Visualization of Object Relations>

By visualizing the network created by entities and relationships, it is intended to intuitively understand the structure. In particular, when the relationships between entities show complex patterns, time required to understand the structure can be saved by visualizing the network. For example, if the data represents the relationship between source and target entities, it is difficult to identify patterns inherent in the data with this data alone. However, if you look at the connection diagram that visualizes this, you can intuitively grasp the patterns contained in the data. It plays an important role in setting the direction of analysis on which objects to pay attention to and which relationships to focus on.

If there is an illegal act between pharmaceutical companies, CSOs, and doctors by utilizing the above-described similarity measurement, network subgroup extraction, entity and relationship visualization techniques, etc., an analysis model can be used to detect it. For rebate research using SNA, elements that can be nodes (objects) are defined, and a matrix between nodes is constructed to derive a relationship (link). In other words, with CSOs, pharmaceutical companies, doctors, etc. as entities, it should be possible to grasp various relationships between these entities, such as fee payments, labor costs, welfare expenses, travel expenses, transportation expenses, and prescriptions. To this end, in order to visualize the relationship between the type and identifier of the entity for rebate investigation and the entity to be grasped, each entity can be displayed in different shapes and colors on the linkage diagram.

Relationships that can be linked with entities such as CSOs, pharmaceutical companies, and doctors can be defined as various relationships depending on the purpose or characteristics of rebate investigations. This enables an intuitive understanding of the structure by displaying a specific entity in a connection diagram and selecting and visualizing a relationship type according to the purpose of investigation. In addition, in order for such a linkage diagram to be effectively used for data analysis, it is necessary to expand the relationship so that objects connected by a specific relationship can be additionally displayed on the linkage diagram based on a series of specified entities. In other words, if one specific person is displayed in the connection diagram, extending the CSO (From) -> To relationship with this person as the basic entity means that when this person is the CSO, the person who was the contractor is extracted from the data. This means that a line is displayed from the primary object to the added person while searching for and adding them to the connection diagram.

The upload unit 330 may receive pharmaceutical company data uploaded from the pharmaceutical company terminal 400 . The pharmaceutical company terminal 400 may upload pharmaceutical company data including products, academic and marketing materials. The CSO terminal 500 may receive pharmaceutical company data from the pharmaceutical company terminal 400 .

The direct performance report unit 340 transfers information from the CSO terminal 500 to the pseudo terminal 600 using the pharmaceutical company data, and the pseudo terminal 600 makes a selective call to the CSO terminal 500 to receive the pharmaceutical company data. And, when a prescription is issued, sales performance may be transmitted to the pharmaceutical company terminal 400 . The pseudo terminal 600 may select and call a CSO of the CSO terminal 500 and receive pharmaceutical company data from the CSO terminal 500 . In general platforms, direct employment effect does not occur because the corporate CSO connects the pharmaceutical company and the individual CSO. However, in the platform according to an embodiment of the present invention, direct performance You will be able to report and get a settlement for it directly.

The remote medical treatment unit 350 may perform non-face-to-face telemedicine when a doctor of the doctor terminal 600 is designated in the patient terminal 100 . The patient terminal 100 may receive non-face-to-face telemedicine by selecting a doctor from the doctor terminal 600 . In this case, you do not have to wait several months in advance in the provinces to go to a famous large hospital and find accommodation near a famous large hospital. At this time, there may be cases in which the doctor facilitates, but in non-face-to-face telemedicine, the acceleration itself is impossible. Accordingly, in one embodiment of the present invention, by using a remote control robot system in the form of a master-slave, it is possible to give a sense of presence, such as a remote doctor facilitating a patient non-face-to-face.

At this time, when performing an act of pushing the remote-controlled robot by applying force to the patient's bone or skin during medical treatment using the remote-controlled robot, the phenomenon of saturation exceeding the control range of the remote-controlled robot actuator due to the contact of the remote-controlled robot This may occur, which may act as an obstacle to sophisticated medical treatment. Therefore, it is decided to use a remote-controlled robot that can be precisely controlled. The contact force of the remote-controlled robot is directly reflected to the master manipulator, and the tactile sensation felt by the operator (doctor) is given by Equation 3 below.

At this time, fs is the contact force of the remote-controlled robot, fr is the tactile sensation felt by the operator through the master manipulator, and Kfr is the force reflection ratio that transmits the contact force of the remote-controlled robot to the operator. If the remote-controlled robot pushes the patient's skin or bone during medical treatment using the remote-controlled robot, as described above, the robot cannot move due to the contact with the remote-controlled robot, and the controller output of the remote-controlled robot is remotely controlled. It may saturate by exceeding the control range of the actuator of the robot. In order to improve such a performance degradation phenomenon, a controller having an anti-windup compensation structure may be used. Of course, it is not limited to the above method.

In addition, the remote medical unit 350 may further provide a cloud-based non-face-to-face medical image reading service. A module for anonymizing patients' personal information and a DB for storing basic information about images can be included in the cloud. As the captured medical images are uploaded to the cloud, the patient's sensitive information in the DICOM tag is anonymized through deletion or change, and a part of the captured image information is stored in the DB. When a radiology specialist accesses the cloud through the reading viewer, among the images that have not been read yet in the information list in the DB, they are connected to the images in the field they are in charge of and read them.

The image reading software may include a dedicated viewer for reading medical images and a report function for results performed through an artificial intelligence module. Through this viewer, a radiologist can read an image that has not yet been read and write and save a report. At this time, the image reading software helps to quickly read the symptoms through an artificial intelligence module. The viewer allows a clearer judgment on the disease area through 2D and 3D rendering, calculates the volume of the labeled disease area, or adjusts the window level of the image to display the disease in the image. Make the area easy to find.

Alternatively, if there is a patient at sea, a marine communication path is established using INMARSAT and MVAST, which are communication paths required for maritime telemedicine, and the smart device and medical device for diagnosis are linked to the marine area. Remote medical treatment can be implemented. By adopting HTTP, a web server can be configured and client requests can be processed, and the patient's chart information can be input using an Android pad application, and the patient can be diagnosed using a Bluetooth electronic stethoscope for diagnosis. In this case, the quality of medical service can be improved by appropriately responding to emergency patients at sea, and an effective medical support system can be provided through linkage with various medical equipment.

The medical data providing unit 360 may upload or crawl data including at least one type of seminar, conference, briefing, introduction of a new product, and how to use equipment from a related institution, and provide the data to the doctor terminal 600 .

The payment unit 370 can make at least one payment in the metaverse platform pay with at least one payment method among at least one type of virtual currency, cryptocurrency, and electronic money. Of course, fiat currencies can also be included.

The statistics unit 380 may generate statistical data by collecting data including fees, business performance, and the number of prescriptions of the pharmaceutical company terminal 400 and the CSO terminal 500 . Statistical evidence from which the number of prescriptions was derived can be set to be uploaded to an Electronic Data Interchange (EDI) system.

The reproduction unit 390 allows the pharmaceutical company terminal 400, the CSO terminal 500, the doctor terminal 600, and the patient terminal 100 to select at least one avatar and enter the metaverse platform, and select at least one avatar. can reproduce the appearance of each object in real time using motion tracking.

The rebate reporting unit 391 may provide a reception counter for reporting rebates at the pharmaceutical company terminal 400 or the CSO terminal 500 . The penalty providing unit 393 collects expenditure reports from the pharmaceutical company terminal 400 and the CSO terminal 500 according to the Sunshine Act, and then provides the pharmaceutical company terminal (which provides a predetermined economic benefit). 400) and a penalty for the CSO terminal 500 may be provided.

The shopping mall provider 395 may incorporate at least one operator in the medical industry that provides medical devices, health functional foods, health care devices, and healthcare services into the metaverse platform, and provide a shopping mall within the metaverse platform. . Of course, the type of at least one business is not limited to those listed.

Hereinafter, an operation process according to the configuration of the above-described platform service providing server of FIG. 2 will be described in detail with reference to FIGS. 3 and 4 as examples. However, it will be apparent that the embodiment is only any one of various embodiments of the present invention, and is not limited thereto.

Referring to FIG. 3A , the platform service providing server 300 provides (a) a pharmaceutical company terminal 400, (b) a CSO terminal 500, (c) a doctor terminal 600, and (d) a patient terminal 100. Register and connect on the metaverse platform. And, as shown in FIG. 3B, which is the second platform, the patient terminal 100 can request and receive remote medical treatment from the doctor terminal 600, and can share information between the doctor terminals 600, and the doctor terminal 600 can 600 can search new drug information or product information provided by the pharmaceutical company terminal 400, and the pharmaceutical company terminal 400 delivers the product to the CSO terminal 500, provides academic data or marketing materials, and provides CSO Communication and information sharing between the terminals 500 can be performed, and when the doctor terminal 600 selects the CSO terminal 500 and makes a call, the CSO of the CSO terminal 500 selects an avatar to be a doctor's hospital, that is, meta It is possible to visit a hospital within the bus platform, and the CSO terminal 500 can provide marketing and information delivery to the avatar of the doctor terminal 600 . In the first platform, which will be described later, each participating doctor submits EDI (statistics) to the platform manager of the present invention, the pharmaceutical company pays and aggregates marketing costs for the total prescription amount to the manager, and the manager calculates the total amount of prescription for each pharmaceutical company's product. can provide. In addition, pharmaceutical companies can share marketing information with each doctor, build big data after prescription, and interact and communicate.

The metaverse platform (tentative name, Medimeta, MEDIMETA) according to an embodiment of the present invention promotes rapid information sharing and drug marketing convenience between pharmaceutical companies, CSOs and doctors, and implements a practical and effective communication method between patients and doctors. Developing the telemedicine market, restoring health insurance financial stability through the eradication of illegal rebates and stabilizing drug prices, and implementing non-face-to-face treatment methods can contribute to the protection and promotion of public health and society. Since CSO does not sell physical drugs, there is no need to face-to-face with doctors, and pharmaceutical companies can quickly share various drug information and marketing information by participating in the Metaverse platform. All CSO fees and policy promotions must be managed transparently, and free competition in good faith based on the concept of market economy must take place. In addition, the doctor does not have to meet only the limited CSO, and must promptly screen and select various CSOs and drug information from various pharmaceutical companies to provide beneficial treatment and prescriptions to patients. Patients no longer want a doctor's prescription in a one-way fashion, and treatment prescriptions must be made through smooth communication between the patient and the doctor.

However, since the current telemedicine applications or other methods are limited to communication prescriptions or video calls and are only the delivery business of physical drugs, the platform (Medimeta) according to an embodiment of the present invention is the beginning of the true telemedicine market. can provide If a metaverse platform is built in which patients, pharmaceutical companies, doctors, and CSOs all participate, the quality of national medical services can be improved because information is shared organically and quickly in real time. At this time, there is no need to separately select a doctor for remote medical treatment, and any doctor within the Metaverse platform can perform remote medical treatment. At the same time, there is no need to select separately, but if the patient wishes, the patient can meet the doctor of the desired hospital and clinic within the Metaverse platform, and treatment and prescription are possible.

In addition, all business related to medical devices and the medical industry can be done within the Metaverse platform, and doctors can freely participate, communicate, and share a wide range of information in virtual space, such as various seminars, conferences, new product introductions, and how to use equipment. there is. In addition, since there is no reason to meet offline, illegal factors can be eliminated, and since illegal factors are eliminated, fair competition is achieved, all markets in the pharmaceutical and medical industries become transparent, and generic drug prices can be normalized. CSOs can freely access hospitals, clinics and doctors within the metaverse platform, and information is delivered and product information is provided at any time, so convenience and pleasure in sales can be added, and above all, anyone can easily sell medicines.

The application according to the prior art connects only to CSO corporations and individual CSOs or other corporate CSOs, and is only at the level of CSO recruitment and information delivery, that is, mediation, and if there is no connection between pharmaceutical companies and applications, according to an embodiment of the present invention The application (Medimeta) allows pharmaceutical companies to participate in the platform of the present invention and freely connects with each CSO so that pharmaceutical companies can freely communicate information, and CSOs directly communicate with various pharmaceutical companies and collect information, Pharmaceutical-related information can be sufficiently delivered to front-line doctors, who are at the final stage of sales.

In the application according to the prior art, the corporate CSO dominates the pharmaceutical company's information and fee system and delivers only filtered information to the individual CSO, but the platform according to an embodiment of the present invention has no subject to control information collection, and this Anyone can upload and collect information within the platform according to an embodiment of the invention. In addition, since individual CSOs directly report sales performance to pharmaceutical companies without going through corporate CSOs, transparency in the Korean pharmaceutical market of 24 trillion won is secured, and CSOs who receive reasonable fee system improvements and the latest information on pharmaceuticals can conduct business activities in a reasonable and easy manner. .

In addition, by directly transacting with pharmaceutical companies, individual CSOs can have fee and policy transparency, and do not have to be subordinated to the opaque corporate CSO. In addition, it is possible to freely communicate with the individual CSO at any time, and since the dependence on the corporate CSO is eliminated, promotion and marketing activities of the company's products become very easy. The same effect as direct employment occurs, and communication between individual CSOs and pharmaceutical companies becomes transparent. In addition, doctors can conveniently access the latest information related to pharmaceutical companies and CSOs in the platform according to an embodiment of the present invention through online seminars, briefings, conferences, etc. with participants, and unnecessary offline meetings are unnecessary. Excessive kickbacks or illegal kickbacks are automatically eradicated.

In addition, the doctor can select the CSO participating in the platform according to an embodiment of the present invention with reference to region, distance, pharmaceutical company, product information transmission ability, etc. can All patients participating in the platform according to an embodiment of the present invention can contact a desired doctor regardless of region or time, and can easily receive detailed consultation and treatment through non-face-to-face contact, and even receive prescriptions. A doctor who accesses the platform according to an embodiment of the present invention can conduct both offline medical treatment and online medical treatment in a medical office.

In summary, anyone can become a CSO, freely sign and market contracts with pharmaceutical companies on the platform according to an embodiment of the present invention, and receive consultations and prescriptions between doctors and patients.

<Platform 1>

Referring to FIGS. 4A and 4B , in another embodiment of the present invention, a pharmaceutical company may introduce a variety of its own products in a platform and utilize them for publicity by using them as marketing-related materials such as clinical results, academic reports, and bioequivalence tests. A number of doctors who have joined the platform can refer to the marketing information of each pharmaceutical company and use it for patient prescription. Current illegal rebate regulations are clearly illegal as they solicit certain doctors to prescribe certain drugs and give a certain amount in cash or other means as a result of the operation. For example, doctors among pharmaceutical company A, pharmaceutical company B, pharmaceutical company C, doctor 1, doctor 2, and doctor 3 participating in this platform may have drugs among the pharmaceutical companies participating in the platform among the drugs they are prescribing. Including cases where a single doctor prescribes multiple products from multiple pharmaceutical companies, performance is announced through monthly prescription statistics of the pharmaceutical company's products within the platform, and the pharmaceutical company is unspecified, that is, which doctor how much? can be kept private Pharmaceutical companies can pay marketing fees for statistics posted by doctors (the sum of data posted by doctors). The platform manager can provide doctors with a certain percentage of the combined sales, that is, prescription statistics/summation by pharmaceutical company, for example, 3%, 5%, 10%, etc., which is the pharmaceutical company's margin.

Among the drugs prescribed by the doctor, that is, of the participating pharmaceutical companies, information that can be obtained in the field, such as prognosis observation, mechanism, clinical, etc. The cost of providing big data is paid in a normal way, for example, by issuing a tax invoice, and transparency is ensured. This is not a business act that prescribes a specific drug to a specific doctor, and an unspecified number of doctors prescribes an unspecified drug with confidence, and the cost that pharmaceutical companies paid through salespeople for marketing promotion is transparently competed in good faith within the platform. It is not an illegal kickback and there is no legal problem because it is paid to all doctors at an exact rate through

As a result, doctors are freed from the temptation of illegal kickbacks and can prescribe with conviction and monitor patients' prognosis, so the quality of medical services is improved, and pharmaceutical companies can reduce or standardize their marketing budgets due to excessive sales , this will soon be stabilized by the normal price setting of the drug, and the financial stability of the National Health Insurance Corporation will be achieved naturally, resulting in cost reduction for the people. The platform according to an embodiment of the present invention can be conducted in the form of a campaign, and the participating doctors and pharmaceutical companies change public awareness of the current pharmaceutical and medical industry, which is stained with illegal rebates, and the doctors and pharmaceutical companies participating in the platform obtains a clean image, which also becomes the basis for marketing promotion, naturally induces the participation of other pharmaceutical companies and doctors, and a sound pharmaceutical market of more than 24 trillion won is achieved. This is the basis of the above-mentioned second platform, that is, the metaverse platform that includes participant CSO and telemedicine.

Matters not described in the metaverse platform service providing method connecting pharmaceutical companies, CSOs, doctors and patients of FIGS. 2 to 4 are metaverse platform services that connect pharmaceutical companies, CSOs, doctors and patients through FIG. 1 above. Since the content described for the providing method is the same as or can be easily inferred from the description, the following description will be omitted.

5 is a diagram showing a process of transmitting and receiving data between each component included in the metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients of FIG. 1 according to an embodiment of the present invention. Hereinafter, an example of a process of transmitting and receiving data between each component will be described through FIG. 5, but the present application is not limited to such an embodiment, and according to various embodiments described above, It is obvious to those skilled in the art that a process of transmitting and receiving data may be changed.

Referring to FIG. 5, the platform service providing server builds a metaverse platform to which pharmaceutical company terminals, CSO terminals, doctor terminals, and patient terminals are connected (S5100).

The platform service providing server receives CSO registration from the CSO terminal, builds a manpower pool (S5200), and uploads pharmaceutical company data from the pharmaceutical company terminal (S5300).

In addition, the platform service providing server transfers information from the CSO terminal to the doctor terminal using the pharmaceutical company data, and receives the pharmaceutical company data by selectively calling the CSO terminal from the doctor terminal, and when a prescription is issued, the sales performance is transmitted to the pharmaceutical company terminal. It is transmitted (S5400).

In addition, the platform service providing server proceeds with non-face-to-face telemedicine when the patient terminal designates a doctor of the doctor terminal (S5500).

The order between the above-described steps (S5100 to S5500) is only an example, and is not limited thereto. That is, the order of the above-described steps (S5100 to S5500) may be mutually changed, and some of the steps may be simultaneously executed or deleted.

Matters not described in the method of providing metaverse platform services that connect pharmaceutical companies, CSOs, doctors, and patients in FIG. 5 are metaverse platform services that connect pharmaceutical companies, CSOs, doctors, and patients through FIGS. 1 to 4 above. Since the content described for the providing method is the same as or can be easily inferred from the description, the following description will be omitted.

The metaverse platform service providing method for connecting pharmaceutical companies, CSOs, doctors and patients according to an embodiment described with reference to FIG. 5 is a record including instructions executable by a computer such as applications or program modules executed by a computer. It can also be implemented in the form of a medium. Computer readable media can be any available media that can be accessed by a computer and includes both volatile and nonvolatile media, removable and non-removable media. Also, computer readable media may include all computer storage media. Computer storage media includes both volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data.

The metaverse platform service providing method for connecting pharmaceutical companies, CSOs, doctors and patients according to an embodiment of the present invention described above is an application basically installed in a terminal (this is a program included in a platform or operating system basically loaded in the terminal). It may be executed by an application store server, an application, or an application (ie, a program) installed directly in the master terminal by a user through an application providing server such as a web server related to the service. In this sense, the metaverse platform service providing method for connecting pharmaceutical companies, CSOs, doctors and patients according to an embodiment of the present invention described above is implemented as an application (ie, a program) that is basically installed in a terminal or directly installed by a user. and can be recorded on a computer-readable recording medium such as a terminal.

The above description of the present invention is for illustrative purposes, and those skilled in the art can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined form.

The scope of the present invention is indicated by the following claims rather than the detailed description above, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts should be construed as being included in the scope of the present invention. do.

Claims (10)

a pharmaceutical company terminal that uploads pharmaceutical company data including products, academic and marketing materials;
a CSO (Contract Sales Organization) terminal receiving pharmaceutical company data from the pharmaceutical company terminal;
a pseudo terminal that selects and calls a CSO of the CSO terminal and receives pharmaceutical company data from the CSO terminal;
a patient terminal to receive non-face-to-face telemedicine by selecting a doctor of the doctor terminal; and
A construction unit that builds a metaverse platform to which the pharmaceutical company terminal, CSO terminal, doctor terminal, and patient terminal are connected, a CSO management unit that receives CSO registration from the CSO terminal and builds a manpower pool, and uploads that receives pharmaceutical company data from the pharmaceutical company terminal. Second, the CSO terminal transmits information to the doctor terminal using the pharmaceutical company data, and the doctor terminal makes a selective call to the CSO terminal to receive the pharmaceutical company data, and when a prescription is issued, the sales performance is transmitted to the pharmaceutical company terminal. a platform service providing server including a direct performance report unit that transmits data to the patient terminal and a remote medical unit that allows non-face-to-face remote medical treatment to be performed when the patient terminal designates a doctor;
Metaverse platform service delivery system that connects pharmaceutical companies, CSOs, doctors and patients, including
According to claim 1,
The platform service providing server,
a medical data providing unit that uploads or crawls data including at least one type of seminar, conference, briefing session, new product introduction, and how to use equipment from related institutions and provides the data to the doctor terminal;
Metaverse platform service delivery system that connects pharmaceutical companies, CSOs, doctors and patients further comprising.
According to claim 1,
The platform service providing server,
At least one cost payment in the metabus platform is a payment unit that allows payment to be made with at least one payment method among at least one type of virtual currency, cryptocurrency and electronic money;
Metaverse platform service delivery system that connects pharmaceutical companies, CSOs, doctors and patients further comprising.
According to claim 1,
The platform service providing server,
a statistical unit generating statistical data by collecting data including commissions, business performance, and number of prescriptions of the pharmaceutical company terminal and the CSO terminal;
Metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients, characterized in that it further comprises.
According to claim 4,
Statistical evidence from which the number of prescriptions is derived is a metaverse platform service providing system that connects pharmaceutical companies, CSOs, doctors and patients, characterized in that uploaded to an Electronic Data Interchange (EDI) system.
According to claim 1,
The platform service providing server,
The pharmaceutical company terminal, CSO terminal, doctor terminal, and patient terminal select at least one avatar to enter the metaverse platform, and the at least one avatar reproduces the appearance of each object in real time using motion tracking. reproducibility;
Metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients, characterized in that it further comprises.
According to claim 1,
The platform service providing server,
a rebate reporting unit providing a reception counter for reporting rebates at the pharmaceutical company terminal or CSO terminal;
Metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients, characterized in that it further comprises.
According to claim 1,
The platform service providing server,
a penalty providing unit that collects expenditure reports from the pharmaceutical company terminals and the CSO terminals according to the Sunshine Act, and then provides penalties to the pharmaceutical company terminals and CSO terminals that have provided predetermined economic benefits;
Metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients, characterized in that it further comprises.
According to claim 1,
The CSO of the CSO terminal is a metaverse platform service providing system that connects pharmaceutical companies, CSOs, doctors and patients, characterized in that it includes a medical representative and a medical marketing specialist.
According to claim 1,
The platform service providing server,
A shopping mall providing unit for incorporating at least one operator in the medical industry that provides medical devices, health functional foods, health care devices, and healthcare services into the metaverse platform and providing a shopping mall within the metaverse platform;
Metaverse platform service providing system connecting pharmaceutical companies, CSOs, doctors and patients, characterized in that it further comprises.

Images